Mirae Asset Global Investments
OVID icon

Mirae Asset Global Investments’s Ovid Therapeutics OVID Stock Holding History

Mirae Asset Global Investments’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,567
Closed -$3.03K – 1650
2024
Q3 		$3.03K Buy
2,567
+449
+21% +$469 ﹤0.01% 1532
2024
Q2 		$1.54K Buy
+2,118
New +$5.89K ﹤0.01% 1516
2024
Q1 		– Sell
-33,996
Closed -$109K – 2592
2023
Q4 		$109K Buy
33,996
+1,765
+5% +$6.03K ﹤0.01% 2449
2023
Q3 		$124K Hold
32,231
– – ﹤0.01% 2421
2023
Q2 		$106K Buy
+32,231
New +$109K ﹤0.01% 2498

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mirae Asset Global Investments's OVID Position: Q4 2024 in Review

Mirae Asset Global Investments sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 2,567 shares — an estimated $3.03K sold.

Mirae Asset Global Investments first reported a position in OVID in Q2 2023 and held it in 5 quarters. The position peaked at $124K in Q3 2023. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • Mirae Asset Global Investments reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,567 Ovid Therapeutics shares in Q4 2024, an estimated $3.03K.
  • Mirae Asset Global Investments first reported a position in Ovid Therapeutics in Q2 2023 and held it in 5 quarters.
  • Mirae Asset Global Investments's Ovid Therapeutics position peaked at $124K in Q3 2023.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on Mirae Asset Global Investments's 13F filing for Q4 2024, filed 27 Jan 2025.